<DOC>
	<DOCNO>NCT00833079</DOCNO>
	<brief_summary>The primary objective establish therapeutic equivalence tacrolimus ointment 0.1 % , manufacture Taro Pharmaceuticals Inc. ProtopicÂ® ( tacrolimus ) , 0.1 % topical ointment ( Astellas Pharma US , Inc. ) show superiority vehicle treatment moderate severe atopic dermatitis . The secondary objective compare adverse event ( AE ) profile two ointment investigate systemic absorption steady state .</brief_summary>
	<brief_title>Bioequivalence Two Tacrolimus 0.1 % Topical Ointment Formulations Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male nonpregnant , nonlactating female , 18 year age old . Patient document evidence unresponsive alternative traditional therapy topical corticosteroid , investigator opinion , first line therapy would deem inadvisable potential risk patient . If female child bear potential , prepare abstain sexual intercourse use reliable method contraception study ( e.g. , condom , IUD , oral , transdermal , injected implant hormonal contraceptive ) . Have confirm diagnosis atopic dermatitis use diagnostic feature describe Hanifin Rajka . Have IGSA score 3 ( moderate ) 4 ( severe ) Have affect Body Surface Area ( BSA ) least 20 % Have minimum Eczema Area Severity Index ( EASI ) score least 15 Mild atopic dermatitis define IGSA score 0 ( clear ) , 1 ( almost clear ) , 2 ( mild ) OR % BSA affect less 20 % OR EASI Score less 15 . Clinically infected atopic dermatitis baseline visit . Tacrolimus indicate treatment clinically infect atopic dermatitis Any dermatological condition atopic dermatitis Investigator 's opinion may interfere evaluation patient 's atopic dermatitis Females pregnant , lactate likely become pregnant study . History allergy sensitivity tacrolimus , pimecrolimus , macrolides clindamycin erythromycin Current diagnosis history disease , Investigators opinion would contraindicate use immunosuppressant , include limited human immunodeficiency virus ( HIV ) cancer . Use nonsteroidal immunosuppressant Regular use intranasal inhaled corticosteroid , great equivalent 2 mg prednisone/day , within 14 day first dose day . Use nonsedating histamine allow least 7 day prior first dose day throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>